MedTrace Logo

Intermittent Preventive Treatment in Infant in Mali

NCT00766662 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL

Last updated 2008-10-06

No results posted yet for this study

Summary

Studies have shown that Intermittent preventive treatment in infants (IPTi) with Sulfadoxine-pyrimethamine (SP)reduced the incidence of clinical malaria and anemia without modifying infants' serological response to EPI vaccines. Thus IPTi was seen as a potential public health tool of great benefit to the children of Africa and a logical addition to the Immunization Plus package. The objectives of this operational researcher were

* to develop an implementation model for IPTi in the health care system in Mali
* to assess its impact on the EPI vaccines and other health interventions coverage
* and on molecular makers of resistance to SP

Conditions

Interventions

DRUG

Sulfadoxine pyrimethamine

Sponsors & Collaborators

  • UNICEF

    collaborator OTHER

  • University of Bamako

    lead OTHER

Principal Investigators

  • Alassane Dicko, MD · Faculty of Medicine, Pharmacy and Dentistry; University of Bamako

  • Ogobara K Doumbo, MD · Faculty of Medicine, Pharmacy and Dentistry; University of Bamako

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
23 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • Mali

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00766662 on ClinicalTrials.gov